Crucell’s Quinvaxem Problems Are Resolved, WHO Says
This article is for subscribers only.
Crucell NV’s manufacturing issues with the Quinvaxem vaccine have been resolved, capping a more than three-month review of contamination at a plant in South Korea, the World Health Organization said.
The WHO will accept supplies of new lots of Quinvaxem and expects the release of newly produced lots to resume this month, the Geneva-based agency said in a statement today.